{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"ADC Therapeutics SA"},"Symbol":{"label":"Symbol","value":"ADCT"},"Address":{"label":"Address","value":"ROUTE DE LA CORNICHE 3B,BIOPOLE, EPALINGES, 1066, Switzerland"},"Phone":{"label":"Phone","value":"+41 216530200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212."},"CompanyUrl":{"label":"Company Url","value":"https://www.adctherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ameet Mallik","title":"President, Chief Executive Officer & Director"},{"name":"David S. Ege","title":"Chief Technical Officer"},{"name":"Mohamed Zaki","title":"Chief Medical Officer"},{"name":"Patrick van Berkel","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}